Koh Young Technology: Strong Q1 2026 Results and Global Expansion of Medical Robot

Consolidated Q1 2026: Revenue KRW 72.7B, Operating Profit KRW 9.9B, Net Income KRW 15.7B (sharp YoY increase)
3D AOI and SPI segments grew 44.5% and 65.1% YoY respectively
Medical robot 'Geniant Cranial' obtained FDA 510(k) (Jan 2025) and Japan PMDA (Jan 2026) approvals
Shareholder return: 2025 year-end dividend of KRW 9.3B (KRW 135 per share), maintaining >20% payout ratio on consolidated net income
Share buyback and cancellation plan approved (Mar 2026 AGM); disposed 168,300 treasury shares in Q1 (approx. KRW 2.3B)
Debt-to-equity ratio 26.8%, stable financial structure; credit ratings A+ to AA-
R&D expenditure 16.6% of revenue (approx. KRW 10.8B), sustaining high investment